FNBT
ACAD icon

FineMark National Bank & Trust’s Acadia Pharmaceuticals ACAD Stock Holding History

FineMark National Bank & Trust’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-200
Closed -$6K – 373
2016
Q4 		$6K Hold
200
– – ﹤0.01% 1027
2016
Q3 		$6K Sell
200
-35
-15% -$1.19K ﹤0.01% 1032
2016
Q2 		$7K Sell
235
-6
-2% -$201 ﹤0.01% 1009
2016
Q1 		$7K Buy
241
+17
+8% +$371 ﹤0.01% 967
2015
Q4 		$8K Buy
224
+12
+6% +$423 ﹤0.01% 971
2015
Q3 		$7K Buy
212
+12
+6% +$499 ﹤0.01% 1027
2015
Q2 		$8K Hold
200
– – ﹤0.01% 1034
2015
Q1 		$7K Sell
200
-49
-20% -$1.68K ﹤0.01% 1057
2014
Q4 		$8K Hold
249
– – ﹤0.01% 1062
2014
Q3 		$6K Buy
249
+19
+8% +$444 ﹤0.01% 1094
2014
Q2 		$6K Hold
230
– – ﹤0.01% 1128
2014
Q1 		$6K Hold
230
– – ﹤0.01% 1129
2013
Q4 		$6K Buy
+230
New +$5.43K ﹤0.01% 1114

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

FineMark National Bank & Trust's ACAD Position: Q1 2017 in Review

FineMark National Bank & Trust sold out of Acadia Pharmaceuticals (ACAD) in Q1 2017, closing a stake of 200 shares — an estimated $6K sold.

FineMark National Bank & Trust first reported a position in ACAD in Q4 2013 and held it in 13 quarters. The position peaked at $8K in Q4 2015. 219 funds tracked by Wall St. Rank hold ACAD as of Q1 2017.

  • FineMark National Bank & Trust reported no remaining Acadia Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • FineMark National Bank & Trust sold 200 Acadia Pharmaceuticals shares in Q1 2017, an estimated $6K.
  • FineMark National Bank & Trust first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 13 quarters.
  • FineMark National Bank & Trust's Acadia Pharmaceuticals position peaked at $8K in Q4 2015.
  • 219 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2017.

Based on FineMark National Bank & Trust's 13F filing for Q1 2017, filed 12 May 2017.